Key result
Higher levels of ischemia-modified albumin were significantly associated with increased arterial stiffness in hemodialysis patients (β = 0.43, P < 0.001).
Why the study?
Increased arterial stiffness is strongly linked to cardiovascular morbidity and mortality in dialysis patients, but the association between the cardiac ischemia biomarker ischemia-modified albumin (IMA) and arterial stiffness in hemodialysis patients required exploration.
Observational (n=120)
No
Absolute Event Rate: 93.7% vs 73.1%
p-value: p=0.027
Ischemia-modified albumin is significantly associated with arterial stiffness in hemodialysis patients and may serve as a useful predictive biomarker.
IMA may signal vascular risk in hemodialysis; leaves open prognostic utility and need for prospective validation.
Increased arterial stiffness is strongly associated with cardiovascular morbidity and mortality in dialysis patients. Ischemia-modified albumin (IMA) is a useful biomarker of cardiac ischemia. This study was aimed to explore the association between IMA and arterial stiffness in hemodialysis patients. An observational study was conducted with 120 hemodialysis patients. Clinical data and laboratory characteristics were collected. Arterial stiffness was evaluated by brachial-ankle pulse wave velocity (baPWV). Hemodialysis patients had extensive arterial stiffness and high levels of IMA. Comparing to hemodialysis patients with normal baPWV, those with high baPWV had significantly higher levels of IMA (93.7 ± 8.6 versus 73.1 ± 10.7 Ku/L, P = 0.027). The multiple linear regression analysis showed that IMA was significantly associated with arterial stiffness in hemodialysis patients (β = 0.43, P < 0.001). Moreover, IMA, with a threshold value of 90.4 Ku/L, provided 77.4% sensitivity and 86.6% specificity for predicting arterial stiffness. Hemodialysis patients with arterial stiffness had high levels of IMA. IMA was a good predictive marker of arterial stiffness for hemodialysis patients.
No takes yet. Share an insight, caveat, or question.
Jiao et al. (2020) conducted an observational in Hemodialysis (n=120). Ischemia-Modified Albumin (IMA) vs. Normal baPWV (< 1400 cm/second) was evaluated on Ischemia-modified albumin levels in patients with high vs normal brachial-ankle pulse wave velocity (baPWV) (p=0.027). Higher levels of ischemia-modified albumin were significantly associated with increased arterial stiffness in hemodialysis patients (β = 0.43, P < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: